BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/2/2021 12:30:25 PM | Browse: 583 | Download: 1033
 |
Received |
|
2020-11-12 07:16 |
|
Peer-Review Started |
|
2020-11-12 07:16 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-02-12 14:30 |
|
Revised |
|
2021-02-16 12:08 |
|
Second Decision |
|
2021-02-24 07:16 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-02-24 21:11 |
|
Articles in Press |
|
2021-02-24 21:11 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-02-26 05:28 |
|
Typeset the Manuscript |
|
2021-03-01 02:36 |
|
Publish the Manuscript Online |
|
2021-03-02 12:30 |
| ISSN |
2308-3840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Efficacy and safety outcomes with remdesivir in COVID-19 patients: A meta-analysis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Tejas Kamleshbhai Patel, Parvati B Patel, Manish Barvaliya, Vijayalaxmi and Hira Lal Bhalla |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tejas Kamleshbhai Patel, MD, Associate Professor, Department of Pharmacology, All India Institute of Medical Sciences, Gorakhpur, Kunraghat, Gorakhpur 273008, Uttar Pradesh, India. dr.tkp2006@yahoo.co.in |
| Key Words |
COVID-19; SARS-CoV-2; Antiviral; Pneumonia; Remdesivir; Meta-analysis; Systematic review |
| Core Tip |
Remdesivir is an antiviral drug having in vitro and in vivo activity against severe acute respiratory syndrome coronavirus 2. United States Food and Drug Administration has granted emergency use authorization for its use in all hospitalized patients. The findings of this meta-analysis suggest remdesivir can enhance clinical recovery without having significant benefits on mortality outcomes. Due to lack of any major safety concerns its use is still recommended in the absence of effective antiviral drugs against coronavirus disease 2019. |
| Publish Date |
2021-03-02 12:30 |
| Citation |
Patel TK, Patel PB, Barvaliya M, Vijayalaxmi, Bhalla HL. Efficacy and safety outcomes with remdesivir in COVID-19 patients: A meta-analysis. World J Meta-Anal 2021; 9(1): 74-87 |
| URL |
https://www.wjgnet.com/2308-3840/full/v9/i1/74.htm |
| DOI |
https://dx.doi.org/10.13105/wjma.v9.i1.74 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
